top of page
Home
What we do
Repurposing
Reformulation
Gold Standard Remodelling
Development Pipeline
About us
ESG
Investors
News
Contact
More
Use tab to navigate through the menu items.
News
18 September 2023
Acquisition of Nuformix plc patents
RNS
20 June 2023
Oxilio announces successful completion of its first clinical trial with OXL001
Read More
6 November 2022
Oxilio announces start of its first clinical trial with OXL001
Read More
29 September 2022
UK Medicines and Healthcare products Regulatory Agency (MHRA) and
Research Ethics Committee (REC) approval for OXL001 clinical trials
Read More
14 April 2022
Launch of Oxilio's ESG policy
Read More
7 April 2022
Oxilio approves 100 for 1 share capital subdivision
30 March 2022
Acquisition of LSHS Consulting Ltd. to secure IP and drug development expertise
Read More
28 March 2022
New Registered Address: Please note this is now 3 Danebrook Court, Langford Lane, Kidlington, Oxford, OX5 1 LQ
21 February 2022
Oxilio OXL001 formulation optimisation and clinical trial preparation contract with Quotient Sciences
Read More
14 February 2022
Clinical evaluation of Oxilio's first novel formulation of OXL001 to commence in partnership with TRx Biosciences
Read More
8 February 2022
Cocrystal formulation optimisation work commissioned with Quotient Sciences
REACH
20 October 2021
Licence agreement with TRx Biosciences Limited
Read More
13 September 2021
Licence agreement with Nuformix plc
RNS
22 March 2021
Exercise of exclusive option agreement with Nuformix plc
RNS
13 January 2021
MOU and Heads of Terms agreement with TRX Biosciences Limited (formerly Biocopea Ltd)
Read More
23 September 2020
Exclusive option agreement with Nuformix plc
RNS
bottom of page
